Permanent cannabis scheme opens new opportunities for businesses
Since 1 January 2026, the Danish medicinal cannabis scheme is no longer temporary. Producers, importers and investors can now plan long-term investments, supply agreements and exports on a stable legal basis.

With Act no. 439 of 6 May 2025, the Danish Parliament made the medicinal cannabis scheme permanent. The Act is now titled the Act on the medicinal cannabis scheme and implements a broad political agreement from November 2024. Patients keep their access to treatment and their reimbursement.
The scheme started as a pilot programme in 2018, and Parliament extended it in 2021 until the end of 2025. At the same time, Parliament gave cultivation and manufacturing a lasting framework. According to the 2024 evaluation, around 1,800 patients used the products, with no signs of safety problems.
New business opportunities in production, import and export
The Danish Medicines Agency (Lægemiddelstyrelsen) continues to grant licences for cultivation, manufacturing and import, and the Agency must enter products on its list before doctors can prescribe them. Two new executive orders from December 2025 set out requirements on quality, security and traceability, including GMP and GACP.
Producers may now also use cannabis that a company in another EU or EEA country has manufactured as an active pharmaceutical ingredient. This opens up new supply agreements and partnerships across borders. Companies can still export cannabis bulk and cannabis primary products to countries that permit imports for medicinal use. Producers may, however, only sell cannabis intermediate products to pharmacies and wholesalers in Denmark.
Clear limits for recreational cannabis and CBD
The commercial opportunities therefore lie in the medicinal market. The Danish Euphoriant Substances Act still prohibits recreational cannabis, and EU law requires Member States to combat illicit trafficking. In 2025, Parliament increased penalties for sales via social media and from shops. Proposals for a trial with legal sales have not won a majority.
For products with a low THC content, Denmark still applies a limit of 0.2 per cent. The EU limit of 0.3 per cent only concerns agricultural support for industrial hemp. The Danish Medicines Agency also considers many CBD oils to be medicinal products that require a marketing authorisation, but the Agency assesses each product individually. In its judgment of 9 March 2023 in case S–1312–21, the Western High Court (Vestre Landsret) acquitted a retailer because the products were neither presented as medicinal products nor had a scientifically established effect.
What should your business do now?
If you are considering entering the market, you should clarify early on whether to cultivate, import or buy from Danish operators, which products to develop, and whether to sell them in Denmark or export them. If you are already active in the market, you should review your licences, quality systems and contracts in light of the new executive orders. If you sell hemp or CBD products, you should clarify their classification before they reach the market.
NJORD's IP team can help your business through the entire process
We also advise on company formation, licences from the Danish Medicines Agency, investment, facilities, supply and export agreements and product classification, and we welcome a no-obligation discussion of your opportunities.












































































































































































































































